(Circulation. 1997;96:61-68.)
© 1997 American Heart Association, Inc.
Articles |
Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease
Fragmin in Unstable Coronary Artery Disease Study (FRIC)
From Graz, Austria (W.K.), Göttingen, Germany (A.B.), Glasgow, UK (S.E.H.), New York, NY ( S.M.), Barcelona, Spain (G.S.), Hamilton, Ontario, Canada (A.G.G.T.), Groningen, the Netherlands (J. van der M.), Pharmacia&Upjohn, Stockholm, Sweden (E.O., S.U.), and Pharmacia & Upjohn, Germany (K.L.).
Correspondence to Prof Werner Klein, MD, Division of Cardiology, Department of Internal Medicine, Auenbruggerplatz 15, A-8036 Graz, Austria.
Background Low-molecular-weight heparin has a number of pharmacological and pharmacokinetic advantages over unfractionated heparin that make it potentially suitable, when used in combination with aspirin, for the treatment of unstable coronary artery disease.
Method and Results Patients with unstable angina or non–Q-wave myocardial infarction (1482) were included in the study, which had two phases. In an open, acute phase (days 1 to 6), patients were assigned either twice-daily weight-adjusted subcutaneous injections of dalteparin (120 IU/kg) or dose-adjusted intravenous infusion of unfractionated heparin. In the double-blind, prolonged treatment phase (days 6 to 45), patients received subcutaneously either dalteparin (7500 IU once daily) or placebo. During the first 6 days, the rate of death, myocardial infarction, or recurrence of angina was 7.6% in the unfractionated heparin-treated patients and 9.3% in the dalteparin-treated patients (relative risk, 1.18; 95% confidence interval [CI], 0.84 to 1.66). The corresponding rates in the two treatment groups for the composite end point of death or myocardial infarction were 3.6% and 3.9%, respectively (relative risk, 1.07; 95% CI, 0.63 to 1.80). Revascularization procedures were undertaken in 5.3% and 4.8% of patients in unfractionated heparin and dalteparin groups, respectively (relative risk, 0.88; 95% CI, 0.57 to 1.35). Between days 6 and 45, the rate of death, myocardial infarction, or recurrence of angina was 12.3% in both the placebo and dalteparin groups (relative risk, 1.01; 95% CI, 0.74 to 1.38). The corresponding rates for death or myocardial infarction were 4.7% and 4.3% (relative risk, 0.92; 95% CI, 0.54 to 1.57). Revascularization procedures were undertaken in 14.2% and 14.3% of patients in the placebo and dalteparin groups, respectively.
Conclusions Our results add to previous evidence suggesting that the low-molecular-weight heparin dalteparin administered by twice-daily subcutaneous injection may be an alternative to unfractionated heparin in the acute treatment of unstable angina or non–Q-wave myocardial infarction. Prolonged treatment with dalteparin at a lower once-daily dose in our study did not confer any additional benefit over aspirin (75 to 165 mg) alone.
Key Words: heparin • angina • myocardial infarction
This article has been cited by other articles:
 |
|
 |
|
  E. A Nutescu, S. A Spinler, A. Wittkowsky, and W. E Dager Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings Ann. Pharmacother., June 1, 2009; 43(6): 1064 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Lopes, K. P. Alexander, S. V. Manoukian, M. E. Bertrand, F. Feit, H. D. White, C. V. Pollack Jr, J. Hoekstra, B. J. Gersh, G. W. Stone, et al. Advanced Age, Antithrombotic Strategy, and Bleeding in Non-ST-Segment Elevation Acute Coronary Syndromes: Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial J. Am. Coll. Cardiol., March 24, 2009; 53(12): 1021 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Lopes, K. P. Alexander, G. Marcucci, H. D. White, S. Spinler, J. Col, P. E. Aylward, R. M. Califf, and K. W. Mahaffey Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial Eur. Heart J., August 1, 2008; 29(15): 1827 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 257S - 298S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Harrington, R. C. Becker, C. P. Cannon, D. Gutterman, A. M. Lincoff, J. J. Popma, G. Steg, G. H. Guyatt, and S. G. Goodman Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 670S - 707S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Mousa, F. Zhang, A. Aljada, S. Chaturvedi, M. Takieddin, H. Zhang, L. Chi, M. C. Castelli, K. Friedman, M. M. Goldberg, et al. Pharmacokinetics and Pharmacodynamics of Oral Heparin Solid Dosage Form in Healthy Human Subjects J. Clin. Pharmacol., December 1, 2007; 47(12): 1508 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): 652 - 726. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Alexander, L. K. Newby, C. P. Cannon, P. W. Armstrong, W. B. Gibler, M. W. Rich, F. Van de Werf, H. D. White, W. D. Weaver, M. D. Naylor, et al. Acute Coronary Care in the Elderly, Part I: Non-ST-Segment-Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology Circulation, May 15, 2007; 115(19): 2549 - 2569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]
|
|
|
|
|
|
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions Circulation, December 19, 2006; 114(25): 2871 - 2891. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-W. Moon, Y.-K. Song, J.-P. Jee, C.-K. Kim, H.-K. Choung, and J.-M. Hwang Effect of subconjunctivally injected, liposome-bound, low-molecular-weight heparin on the absorption rate of subconjunctival hemorrhage in rabbits. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3968 - 3974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-M. Myint, Y. Yamamoto, T. Doi, I. Kato, A. Harashima, H. Yonekura, T. Watanabe, H. Shinohara, M. Takeuchi, K. Tsuneyama, et al. RAGE Control of Diabetic Nephropathy in a Mouse Model: Effects of RAGE Gene Disruption and Administration of Low-Molecular Weight Heparin Diabetes, September 1, 2006; 55(9): 2510 - 2522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Schiff, S. R. Kahn, I. Shrier, C. Strulovitch, W. Hammouda, E. Cohen, and D. Zukor Identifying Orthopedic Patients at High Risk for Venous Thromboembolism Despite Thromboprophylaxis Chest, November 1, 2005; 128(5): 3364 - 3371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]
|
|
|
|
|
|
J. S Kalus and L. R Moser Evolving Role of Low-Molecular-Weight Heparins in ST-Elevation Myocardial Infarction Ann. Pharmacother., March 1, 2005; 39(3): 481 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R Moser and J. S Kalus Role of Low-Molecular-Weight Heparin in Invasive Management of Non-ST-Elevation Acute Coronary Syndromes Ann. Pharmacother., December 1, 2004; 38(12): 2094 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Wiggins and S. Spinler Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes Journal of Pharmacy Practice, October 1, 2004; 17(5): 347 - 369. [Abstract] [PDF]
|
|
|
|
|
|
M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 287S - 310S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Harrington, R. C. Becker, M. Ezekowitz, T. W. Meade, C. M. O'Connor, D. A. Vorchheimer, and G. H. Guyatt Antithrombotic Therapy for Coronary Artery Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 513S - 548S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Macie, L. Forbes, G. A. Foster, and J. D. Douketis Dosing Practices and Risk Factors for Bleeding in Patients Receiving Enoxaparin for the Treatment of an Acute Coronary Syndrome Chest, May 1, 2004; 125(5): 1616 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fareed, Q. Ma, M. Florian, J. Maddineni, O. Iqbal, D. A. Hoppensteadt, and R. Bick Unfractionated and Low-Molecular-Weight Heparins, Basic Mechanism of Action and Pharmacology Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 357 - 377. [Abstract] [PDF]
|
|
|
|
|
|
A. Prasad, V. Mathew, D. R Holmes Jr., and B. J Gersh Current management of non-ST-segment-elevation acute coronary syndrome: reconciling the results of randomized controlled trials Eur. Heart J., September 1, 2003; 24(17): 1544 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Bijsterveld, A. H. Moons, J. C. M. Meijers, M. Levi, H. R. Buller, and R. J. G. Peters The impact on coagulation of an intravenous loading dose in addition to a subcutaneousregimen of low-molecular-weight heparinin the initial treatment of acute coronary syndromes J. Am. Coll. Cardiol., August 6, 2003; 42(3): 424 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Kincaid, M. L. Monroe, D. L. Saliba, N. D. Kon, W. G. Byerly, and M. G. Reichert Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting Ann. Thorac. Surg., July 1, 2003; 76(1): 124 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A Nutescu, R. K Lewis, J. M Finley, and G. T Schumock Hospital Guidelines for Use of Low-Molecular-Weight Heparins Ann. Pharmacother., July 1, 2003; 37(7): 1072 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon and A. G.G. Turpie Unstable Angina and Non-ST-Elevation Myocardial Infarction: Initial Antithrombotic Therapy and Early Invasive Strategy Circulation, June 3, 2003; 107(21): 2640 - 2645. [Full Text] [PDF]
|
|
|
|
|
|
L. Wallentin, L. Bergstrand, M. Dellborg, C. Fellenius, C. B Granger, B. Lindahl, L.-E. Lins, T. Nilsson, K. Pehrsson, A. Siegbahn, et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction--the ASSENT Plus study Eur. Heart J., May 2, 2003; 24(10): 897 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I P Casserly and E J Topol The primacy of clinical effectiveness for cost effectiveness analysis Heart, March 1, 2003; 89(3): 249 - 250. [Full Text] [PDF]
|
|
|
|
|
|
M Janzon, L-A Levin, and E Swahn Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial Heart, March 1, 2003; 89(3): 287 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. S. Monroe, R. A. Kerensky, E. Rivera, K. M. Smith, and C. J. Pepine Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 23S - 30S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cohen The role of low-molecular-weight heparin in the management of acute coronary syndromes J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 55S - 61S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Marmur, S. X. Anand, R. S. Bagga, J. Fareed, C.-M. Pan, S. K. Sharma, and M. F. Richard The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration J. Am. Coll. Cardiol., February 5, 2003; 41(3): 394 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Wong, R. P. Giugliano, and E. M. Antman Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention JAMA, January 15, 2003; 289(3): 331 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-U. Esslinger, S. Kohne, P. Radziwon, J. M. Walenga, and H. K. Breddin Effects of PEG-Hirudin in Clotting Parameters and Platelet Function and its Interaction with Aspirin in Healthy Volunteers Clinical and Applied Thrombosis/Hemostasis, January 1, 2003; 9(1): 79 - 88. [Abstract] [PDF]
|
|
|
|
|
|
J. Borja Enoxaparin in unstable coronary artery disease Eur. Heart J., October 2, 2002; 23(20): 1632 - 1632. [Full Text] [PDF]
|
|
|
|
|
|
C.P. Cannon A reply Eur. Heart J., October 2, 2002; 23(20): 1633 - 1634. [Full Text] [PDF]
|
|
|
|
|
|
S.E. Husted, L. Wallentin, B. Lagerqvist, F. Kontny, E. Stahle, and E. Swahn Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization Eur. Heart J., August 1, 2002; 23(15): 1213 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Cohen, D. G. Murphy, and J. Williams Review of the Current ACS Practice Guideline to Develop an Ischemic Chest Pain Protocol Journal of Pharmacy Practice, June 1, 2002; 15(3): 250 - 266. [Abstract] [PDF]
|
|
|
|
 |
|
 J.J. Ferguson Antithrombin therapy, antiplatelet therapy and percutaneous coronary intervention: rationale and design of the SYNERGY trial Eur. Heart J. Suppl., May 1, 2002; 4(suppl_E): E2 - E9. [Abstract] [PDF]
|
|
|
|
 |
|
 W. Ageno and A. G.G. Turpie New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins Can. Med. Assoc. J., April 1, 2002; 166(7): 919 - 924. [Full Text] [PDF]
|
|
|
|
|
|
N. R. Bijsterveld, A. H. Moons, J. C. M. Meijers, J. G. P. Tijssen, H. R. Buller, M. Levi, and R. J. G. Peters Rebound thrombin generation after heparin therapy in unstable angina: A randomized comparison between unfractionated and low-molecular-weight heparin J. Am. Coll. Cardiol., March 6, 2002; 39(5): 811 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Borja, M. A. Paz, P. Olivella, and R. A. O'Rourke New Approaches to Diagnosis and Management of Unstable Angina and Non-ST Segment Elevation Myocardial Infarction: Controversial Data Arch Intern Med, February 25, 2002; 162(4): 485 - 486. [Full Text] [PDF]
|
|
|
|
|
|
J.J. Ferguson Moving beyond unfractionated heparin for acute coronary syndromes: Xeno's Paradox revisited Eur. Heart J., February 2, 2002; 23(4): 264 - 268. [Full Text] [PDF]
|
|
|
|
|
|
A. Kher and M.M. Samama Low-Molecular-Weight Heparins: Weeks or Months Instead of Days of Treatment Clinical and Applied Thrombosis/Hemostasis, October 1, 2001; 7(4): 314 - 320. [Abstract] [PDF]
|
|
|
|
|
|
A. M. Ross, P. Molhoek, C. Lundergan, M. Knudtson, Y. Draoui, L. Regalado, V. Le Louer, F. Bigonzi, W. Schwartz, E. de Jong, et al. Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin: Second Trial of Heparin and Aspirin Reperfusion Therapy (HART II) Circulation, August 7, 2001; 104(6): 648 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Arterioscler Thromb Vasc Biol, July 1, 2001; 21 (7): e9 - e9. [Full Text] [PDF]
|
|
|
|
|
|
A. G. G. Turpie and E. M. Antman Low-Molecular-Weight Heparins in the Treatment of Acute Coronary Syndromes Arch Intern Med, June 25, 2001; 161(12): 1484 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Circulation, June 19, 2001; 103(24): 2994 - 3018. [Full Text] [PDF]
|
|
|
|
|
|
R. Hodl, K. Huber, W. Kraxner, and W. Klein Limitation of vWf meta-analysis in LMWH comparison J. Am. Coll. Cardiol., June 1, 2001; 37(7): 2006 - 2006. [Full Text] [PDF]
|
|
|
|
|
|
G. Montalescot Reply J. Am. Coll. Cardiol., June 1, 2001; 37(7): 2006 - 2007. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman The Search for Replacements for Unfractionated Heparin Circulation, May 8, 2001; 103(18): 2310 - 2314. [Full Text] [PDF]
|
|
|
|
|
|
G. N. Levine, M. N. Ali, and A. I. Schafer Antithrombotic Therapy in Patients With Acute Coronary Syndromes Arch Intern Med, April 9, 2001; 161(7): 937 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. De Lorenzo, A. Noorani, and V.V. Kakkar Current trends in the management of thromboembolic events QJM, April 1, 2001; 94(4): 179 - 185. [Full Text] [PDF]
|
|
|
|
|
|
The Organization to Assess Strategies for Ischemic Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina J. Am. Coll. Cardiol., February 1, 2001; 37(2): 475 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
British Cardiac Society Guidelines and Medical Pra and Royal College of Physicians Clinical Effectiveness Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation Heart, February 1, 2001; 85(2): 133 - 142. [Full Text]
|
|
|
|
|
|
J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman, and J. E. Dalen Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety Chest, January 1, 2001; 119 (2009): 64S - 94S. [Full Text] [PDF]
|
|
|
|
|
|
M. N. Levine, G. Raskob, S. Landefeld, and C. Kearon Hemorrhagic Complications of Anticoagulant Treatment Chest, January 1, 2001; 119 (2009): 108S - 121S. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cairns, P. Theroux, H. D. Lewis Jr., M. Ezekowitz, and T. W. Meade Antithrombotic Agents in Coronary Artery Disease Chest, January 1, 2001; 119 (2009): 228S - 252S. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Manhapra and S. Borzak Regular review: Treatment possibilities for unstable angina BMJ, November 18, 2000; 321(7271): 1269 - 1275. [Full Text]
|
|
|
|
|
|
J. Borja, J. I. Weitz, and S. M. Bates Dalteparin for Unstable Angina and Non-Q-Wave Myocardial Infarction Arch Intern Med, November 13, 2000; 160(20): 3169 - 3170. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Ageno and A. G. Turpie Therapy of unstable angina with the low molecular weight heparins Vascular Medicine, November 1, 2000; 5(4): 217 - 223. [Abstract] [PDF]
|
|
|
|
|
|
G. G Nenci and A. Minciotti Low molecular weight heparins for arterial thrombosis Vascular Medicine, November 1, 2000; 5(4): 251 - 258. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Kalafut, R. Gandhi, C. S. Kidwell, and J. L. Saver Safety and Cost of Low-Molecular-Weight Heparin as Bridging Anticoagulant Therapy in Subacute Cerebral Ischemia Stroke, November 1, 2000; 31(11): 2563 - 2568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Goodman, M. Cohen, F. Bigonzi, E. P. Gurfinkel, D. R. Radley, V. Le Iouer, G. J. Fromell, C. Demers, A. G. G. Turpie, R. M. Califf, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the essence study J. Am. Coll. Cardiol., September 1, 2000; 36(3): 693 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) J. Am. Coll. Cardiol., September 1, 2000; 36(3): 970 - 1062. [Full Text] [PDF]
|
|
|
|
|
|
M.E Bertrand, M.L Simoons, K.A.A Fox, L.C Wallentin, C.W Hamm, E McFadden, P.J de Feyter, G Specchia, and W Ruzyllo Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology: Recommendations of the Task Force of the European Society of Cardiology Eur. Heart J., September 1, 2000; 21(17): 1406 - 1432. [PDF]
|
|
|
|
|
|
T. Hammoud, J.-F. Tanguay, and M. G. Bourassa Management of coronary artery disease: therapeutic options in patients with diabetes J. Am. Coll. Cardiol., August 1, 2000; 36(2): 355 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Heeschen, B.U. Goldmann, W. Terres, and C.W. Hamm Cardiovascular risk and therapeutic benefit of coronary interventions for patients with unstable angina according to the troponin T status Eur. Heart J., July 2, 2000; 21(14): 1159 - 1166. [Abstract] [PDF]
|
|
|
|
|
|
G. Montalescot, J. P. Collet, L. Lison, R.e. Choussat, A. Ankri, E. Vicaut, K. Perlemuter, F. Philippe, G.e. Drobinski, and D. Thomas Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina J. Am. Coll. Cardiol., July 1, 2000; 36(1): 110 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kaul and P. K. Shah Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1699 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Abrahamsson, A Rosengren, and M Dellborg Improved long-term prognosis for patients with unstable coronary syndromes 1988-1995 Eur. Heart J., April 1, 2000; 21(7): 533 - 539. [Abstract] [PDF]
|
|
|
|
|
|
J. I. Weitz and S. M. Bates Beyond Heparin and Aspirin: New Treatments for Unstable Angina and Non-Q-Wave Myocardial Infarction Arch Intern Med, March 27, 2000; 160(6): 749 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Clark, N. Vitale, J. Zacharias, and J. Forty Effect of low molecular weight heparin (Fragmin) on bleeding after cardiac surgery Ann. Thorac. Surg., March 1, 2000; 69(3): 762 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yeghiazarians, J. B. Braunstein, A. Askari, and P. H. Stone Unstable Angina Pectoris N. Engl. J. Med., January 13, 2000; 342(2): 101 - 114. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ambrose and G. Dangas Unstable Angina: Current Concepts of Pathogenesis and Treatment Arch Intern Med, January 10, 2000; 160(1): 25 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O. Cheng Low-Molecular-Weight Heparin for Unstable Angina Chest, December 1, 1999; 116(6): 1833 - 1833. [Full Text] [PDF]
|
|
|
|
|
|
L. Wallentin New trials of LMW heparins -- light and heavy weight as good on short but what about longer distances? Eur. Heart J., November 1, 1999; 20(21): 1522 - 1524. [PDF]
|
|
|
|
|
|
H. Purcell and K.M. Fox Improving outcome in acute coronary syndromes -- as good as it gets? Eur. Heart J., November 1, 1999; 20(21): 1533 - 1537. [PDF]
|
|
|
|
|
|
The Frax.I.S. Study Group Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome) Eur. Heart J., November 1, 1999; 20(21): 1553 - 1562. [Abstract] [PDF]
|
|
|
|
|
|
P. W. Armstrong Pursuing Progress in Acute Coronary Syndromes Circulation, October 12, 1999; 100(15): 1586 - 1589. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman, C. H. McCabe, E. P. Gurfinkel, A. G. G. Turpie, P. J. L. M. Bernink, D. Salein, A. Bayes de Luna, K. Fox, J.-M. Lablanche, D. Radley, et al. Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction : Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial Circulation, October 12, 1999; 100(15): 1593 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman, M. Cohen, D. Radley, C. McCabe, J. Rush, J. Premmereur, and E. Braunwald Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non-Q-Wave Myocardial Infarction : TIMI 11B-ESSENCE Meta-Analysis Circulation, October 12, 1999; 100(15): 1602 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Bick and J. Rice Long-Term Outpatient Dalteparin (Fragmin) Therapy for Arterial and Venous Thrombosis: Efficacy and Safety--A Preliminary Report Clinical and Applied Thrombosis/Hemostasis, October 1, 1999; 5(1_suppl): S67 - S71. [Abstract] [PDF]
|
|
|
|
|
|
P. J. Zed, J. E. Tisdale, and S. Borzak Low-Molecular-Weight Heparins in the Management of Acute Coronary Syndromes Arch Intern Med, September 13, 1999; 159(16): 1849 - 1857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lloyd, C. C Callander, K. Stein, T. Nicholson, and N. Grubb The end of the heparin pump? BMJ, August 28, 1999; 319(7209): 575a - 575. [Full Text]
|
|
|
|
|
|
C. E. Chambers, S. T Riebel, and M. Kozak Interventional Cardiology: Advances in Percutaneous Techniques for the Treatment of Cardiac Disease Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 1999; 3(2): 109 - 125. [Abstract] [PDF]
|
|
|
|
|
|
S KENNON and A TIMMIS Management of unstable angina: what role intervention, ask the RITA-3 trialists? Heart, June 1, 1999; 81(6): 565 - 566. [Full Text]
|
|
|
|
|
|
T. O. Cheng Weight Watching in Heparin Arch Intern Med, May 24, 1999; 159(10): 1142 - 1142. [Full Text] [PDF]
|
|
|
|
|
|
B. L. Norgaard, K. Andersen, M. Dellborg, P. Abrahamsson, J. Ravkilde, K. Thygesen, and for the TRIM study group Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1519 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Frostfeldt, G. Ahlberg, G. Gustafsson, G. Helmius, B. Lindahl, A. Nygren, A. Siegbahn, E. Swahn, P. Venge, and L. Wallentin Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction--a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II) J. Am. Coll. Cardiol., March 1, 1999; 33(3): 627 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Bates and J. I. Weitz Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin Cardiovasc Res, February 1, 1999; 41(2): 418 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Hotline Editorial Eur. Heart J., January 1, 1999; 20(1): 7 - 10. [PDF]
|
|
|
|
|
|
R. A. Baughman, S. C. Kapoor, R. K. Agarwal, J. Kisicki, F. Catella-Lawson, and G. A. FitzGerald Oral Delivery of Anticoagulant Doses of Heparin : A Randomized, Double-Blind, Controlled Study in Humans Circulation, October 20, 1998; 98(16): 1610 - 1615. [Abstract] [Full Text] [PDF]
|
|